NICE has published draft guidance stating that although Translarna (also known as ataluren) is clinically effective and an innovative treatment, there is doubt as to its cost effectiveness. NICE’s draft recommendation is that people currently receiving Translarna should continue to have access to it until they and their NHS clinician consider it appropriate to stop,…
Category: Uncategorised
Breakthrough in identifying common neural processes in Parkinson’s disease
New research could lead to treatments that halt the advance of Parkinson’s disease. Study from University of Haifa could have significant implications for how Parkinson’s disease is treated following a breakthrough in identifying common neural processes for the first time. A new study conducted by University of Haifa has identified processes that may help prevent…
AJOVY®▼ (fremanezumab) for treatment of migraine in patients with co-morbid depression
Two separate analyses1,2 presented at the Migraine Trust International Symposium (MTIS) demonstrate the effectiveness of AJOVY▼(fremanezumab) for the treatment of migraine in patients with migraine and co-morbid depression Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine3,4 and are associated with more pain, disability and a reduced quality of…
Blood type may be linked to risk of early stroke
Gene variants associated with a person’s blood type may be linked to their risk of early stroke, according to a new meta-analysis published in the August 31, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. The meta-analysis included all available data from genetic studies that included young adult ischaemic stroke, which…
International Encephalitis Research Seed Funding 2022
Deadline: 9th September 2022 The Encephalitis Society are inviting researchers to apply for up to £10,000 in seed funding for a project specific on encephalitis with a duration of up to 18 months. The fund is open to applicants from low-to-middle income countries worldwide and to all levels from medical students, junior doctors and early…
First ever Marketing Authorisation Application (MAA) for biosimilar natalizumab
Polpharma Biologics announced on July 15th 2022 that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorisation Application (MAA) for biosimilar natalizumab, a proposed biosimilar to Tysabri®. In the European Union, Tysabri is approved to treat adults with relapsing-remitting MS (RRMS) who have highly active disease. It is approved for adults with relapsing…
Trial shows benefits in patients with Duchenne Muscular Dystrophy
Topline Data from Phase 3 Trial shows beneficial effect of Givinostat 22nd June, 2022: Italfarmaco Group announced positive topline data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in boys with Duchenne Muscular Dystrophy (DMD). The primary objective of the study was to evaluate the effects of Givinostat…
Breakthrough device for glioblastoma
Carthera receives FDA breakthrough device designation for SonoCloud-9 system, allowing for enhanced interaction with FDA and recognising SonoCloud system as innovative and promising approach for treatment of recurrent glioblastoma Carthera, a French company that designs and develops SonoCloud, an ultrasound-based medical device to treat a wide range of brain diseases, announced on June 22 2022 that…
Study: Improvements in TBI Patients with Persistent Brain Fog
A new study has shown that plasticity-based brain training can drive improvements in patients with persistent symptoms of Traumatic Brain Injury (TBI). Gains were observed in standard measures of cognition, standard measures of self-reported symptoms, and the connectivity between brain regions. The intervention used in the study was brain exercises from BrainHQ, made by Posit…
